We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$240M
AUM Growth
-$51.7M
Cap. Flow
+$25.2M
Cap. Flow %
10.52%
Top 10 Hldgs %
50.22%
Holding
91
New
10
Increased
29
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$6.75M
2
CGEN icon
Compugen
CGEN
+$4.71M
3
AGTC
Applied Genetic Technologies Corporation
AGTC
+$4.22M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.78M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.7M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$9.94M
2
CYTK icon
Cytokinetics
CYTK
+$4.44M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$3.7M
4
ATRC icon
AtriCure
ATRC
+$2.84M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 91.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
26
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.71M 1.13%
147,714
+29,400
+25% +$571K
SIOX
27
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.49M 1.04%
+1,021,566
New +$3.69M
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
$2.34M 0.98%
16,065
+11,726
+270% +$2.05M
KDMN
29
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.33M 0.97%
556,564
+182,141
+49% +$784K
BEAT
30
DELISTED
BioTelemetry, Inc.
BEAT
$2.33M 0.97%
60,500
+5,200
+9% +$239K
VKTX icon
31
Viking Therapeutics
VKTX
$4B
$2.11M 0.88%
450,900
+241,700
+116% +$1.49M
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.1M 0.87%
46,908
+16,500
+54% +$876K
CSII
33
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.8M 0.75%
51,200
+5,000
+11% +$211K
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$1.8M 0.75%
234,952
+210,227
+850% +$2.84M
AFMD
35
DELISTED
Affimed
AFMD
$1.79M 0.75%
113,340
-16
-0% -$381
HARP
36
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.71M 0.71%
+14,747
New +$2.07M
EPZM
37
DELISTED
Epizyme, Inc
EPZM
$1.64M 0.69%
105,900
+37,900
+56% +$814K
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
$1.45M 0.6%
54,054
+13,397
+33% +$476K
AUTL
39
Autolus Therapeutics
AUTL
$562M
$1.32M 0.55%
219,800
+119,800
+120% +$1.11M
ARAY icon
40
Accuray
ARAY
$34M
$1.28M 0.53%
674,300
– –
JNJ icon
41
Johnson & Johnson
JNJ
$625B
$1.23M 0.51%
9,400
– –
INGN icon
42
Inogen
INGN
$164M
$1.19M 0.5%
23,000
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$1.17M 0.49%
1,969
– –
ZYME icon
44
Zymeworks
ZYME
$1.73B
$1.14M 0.47%
+32,000
New +$1.31M
PHAS
45
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.06M 0.44%
320,542
-40,000
-11% -$183K
ARDX icon
46
Ardelyx
ARDX
$988M
$1.05M 0.44%
184,850
-15,000
-8% -$102K
NTUS
47
DELISTED
Natus Medical Inc
NTUS
$992K 0.41%
42,900
– –
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.4B
$958K 0.4%
479,051
-35,000
-7% -$96.4K
STIM icon
49
Neuronetics
STIM
$166M
$937K 0.39%
495,772
+100,000
+25% +$313K
GNCA
50
DELISTED
Genocea Biosciences, Inc.
GNCA
$933K 0.39%
542,564
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, DAFNA Capital Management held 91 positions worth $240M, down 18% from $291M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $25.2M of net new capital in Q1 2020, opening 10 new positions and adding to 29 existing holdings. Its largest new stake was Compugen: 600,000 shares worth $4.36M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.84M trimmed.

  • DAFNA Capital Management's largest Q1 2020 buy was Compugen: 600,000 shares worth $4.36M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q1 2020, an estimated $6.75M increase.
  • DAFNA Capital Management's biggest Q1 2020 reduction was AtriCure, cutting an estimated $2.84M.
  • DAFNA Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $9.94M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $240M portfolio in Q1 2020.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q1 2020.
  • DAFNA Capital Management's portfolio value fell 18% quarter-over-quarter to $240M.

Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.